Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases.

Literature DB >> 23426496

New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases.

Sumaira Aasi, Rona Silkiss, Jean Y Tang, Ashley Wysong, Andy Liu, Ervin Epstein, Anthony E Oro, Anne Lynn S Chang.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2013 PMID： 23426496 PMCID： PMC3768013 DOI： 10.1001/jamadermatol.2013.1798

Source DB: PubMed Journal: JAMA Dermatol ISSN： 2168-6068 Impact factor: 10.282

× No keyword cloud information.

3 in total

1. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.

Authors: Zita Dubauskas; Joy Kunishige; Victor G Prieto; Eric Jonasch; Patrick Hwu; Nizar M Tannir
Journal: Clin Genitourin Cancer Date: 2009-01 Impact factor: 2.872

2. Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients.

Authors: O Epaulard; C Saint-Raymond; C Villier; J Charles; N Roch; J-C Beani; M-T Leccia
Journal: Clin Microbiol Infect Date: 2010-09 Impact factor: 8.067

3. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Authors: Fei Su; Amaya Viros; Carla Milagre; Kerstin Trunzer; Gideon Bollag; Olivia Spleiss; Jorge S Reis-Filho; Xiangju Kong; Richard C Koya; Keith T Flaherty; Paul B Chapman; Min Jung Kim; Robert Hayward; Matthew Martin; Hong Yang; Qiongqing Wang; Holly Hilton; Julie S Hang; Johannes Noe; Maryou Lambros; Felipe Geyer; Nathalie Dhomen; Ion Niculescu-Duvaz; Alfonso Zambon; Dan Niculescu-Duvaz; Natasha Preece; Lídia Robert; Nicholas J Otte; Stephen Mok; Damien Kee; Yan Ma; Chao Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Hoa Nguyen; Mark Kockx; Luc Andries; Brian Lestini; Keith B Nolop; Richard J Lee; Andrew K Joe; James L Troy; Rene Gonzalez; Thomas E Hutson; Igor Puzanov; Bartosz Chmielowski; Caroline J Springer; Grant A McArthur; Jeffrey A Sosman; Roger S Lo; Antoni Ribas; Richard Marais
Journal: N Engl J Med Date: 2012-01-19 Impact factor: 91.245

3 in total

12 in total

1. RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.

Authors: Xuesong Zhao; Tatyana Ponomaryov; Kimberly J Ornell; Pengcheng Zhou; Sukriti K Dabral; Ekaterina Pak; Wei Li; Scott X Atwood; Ramon J Whitson; Anne Lynn S Chang; Jiang Li; Anthony E Oro; Jennifer A Chan; Joseph F Kelleher; Rosalind A Segal
Journal: Cancer Res Date: 2015-06-30 Impact factor: 12.701

New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases.

1. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.

2. Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients.

3. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

1. RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.

2. Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.

3. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.

Review 4. Sonic hedgehog signaling in Basal cell nevus syndrome.

Review 5. Ionizing Radiation Exposure and Basal Cell Carcinoma Pathogenesis.

Review 6. Genetic and environmental factors underlying keratinocyte carcinoma risk.

7. Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib.

8. Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma.

Review 9. Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors.

10. Unusual and Interesting Adverse Cutaneous Drug Reactions.